Allergan Licenses Phase I Skin Cancer Drug from Peplin
By Business Review Editor
Pharma Deals Review: Vol 2002 Issue 31 (Table of Contents)
Published: 2 Dec-2002
DOI: 10.3833/pdr.v2002.i31.966 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Allergan acquired the rights to PEP 005 product useful for treating nonmelanoma skin cancer and actinic keratosis from Peplin Biotech...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.
RSS